NVAX Relative Valuation
NVAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NVAX is overvalued; if below, it's undervalued.
Historical Valuation
Novavax Inc (NVAX) is now in the Fair zone, suggesting that its current forward PS ratio of 1.86 is considered Fairly compared with the five-year average of 2.44. The fair price of Novavax Inc (NVAX) is between 4.46 to 17.77 according to relative valuation methord.
Relative Value
Fair Zone
4.46-17.77
Current Price：7.25
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
-14.41
P/B
Median3y
-0.88
Median5y
7.54
-19.30
FCF Yield
Median3y
-57.42
Median5y
-33.89
Competitors Valuation Multiple
The average P/S ratio for NVAX's competitors is 3.95, providing a benchmark for relative valuation. Novavax Inc Corp (NVAX) exhibits a P/S ratio of 1.86, which is -52.82% above the industry average. Given its robust revenue growth of 610.30%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Novavax Inc (NVAX) currently overvalued or undervalued?
What is Novavax Inc (NVAX) fair value?
How does NVAX's valuation metrics compare to the industry average?
What is the current P/B ratio for Novavax Inc (NVAX) as of May 24 2025?
What is the current FCF Yield for Novavax Inc (NVAX) as of May 24 2025?
What is the current Forward P/E ratio for Novavax Inc (NVAX) as of May 24 2025?